Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Phenotyping Sarcoidosis-Associated Pulmonary Hypertension: A Review of Pathophysiology and Management.

Created on 16 Nov 2026

Authors

Mohamed I Seedahmed, Jetina Okereke, Natalia V Rivera, Mazen O Al-Qadi

Published in

Therapeutic advances in pulmonary and critical care medicine. Volume 21. Pages 29768675261485674. Epub Oct 01, 2026.

Abstract

Sarcoidosis-associated pulmonary hypertension (SAPH) is a significant yet often overlooked complication of sarcoidosis that profoundly affects both morbidity and mortality rates. The development of SAPH illustrates the intricate relationship among lung tissue damage, granulomatous inflammation of blood vessels, and remodeling of cardiac or vascular structures. This complexity highlights the multifaceted nature of sarcoidosis pathophysiology. In this review, we delve into key topics, including epidemiology, underlying mechanisms, and current treatment options, while also discussing the path forward for precision medicine applications. SAPH serves as a clear example of the systemic and vascular intricacies of sarcoidosis, connecting immune-mediated granulomatous inflammation with pulmonary vascular involvement. By gaining a deeper understanding of its unique molecular, hemodynamic, and imaging characteristics, we can enhance risk stratification and therapeutic decision-making, ultimately paving the way for more tailored management of sarcoidosis.

PMID:
43036554
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement